BNTXBioNTech SESigning up patients
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Endometrial Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 480 (planned)
- Started
- Jun 10, 2025
- Main results expected
- Mar 2028
- Fully finished
- Nov 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohort 1: PFS assessed by blinded independent central review (BICR) in participants with HER2 IHC 1+/2+ recurrent endometrial cancer
Measured over: Up to approximately 53 months
Cohort 2: ORR assessed by BICR in participants with HER2 IHC 3+ recurrent endometrial cancer
Measured over: Up to approximately 53 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06340568 · record last updated 2026-10-16 · checked 2026-11-09 15:47 UTC